Literature DB >> 8612131

The specificity and orientation of a TCR to its peptide-MHC class II ligands.

D B Sant'Angelo1, G Waterbury, P Preston-Hurlburt, S T Yoon, R Medzhitov, S C Hong, C A Janeway.   

Abstract

A T cell-mediated immune response is mainly determined by the 3-5 aa residues that protrude upwards from a peptide bound to an MHC molecule. Alterations of these peptide residues can diminish, eliminate or radically alter the signal that the T cell receives through its T cell receptor (TCR). We have used peptide immunizations of normal mice and mice carrying alpha or beta chain TCR transgenes to identify three distinct peptide contact points. One, near the carboxyl terminus of the peptide, involves the beta chain CDR3 region; the second was centrally located and interacted with both the alpha and beta chain CDR3 loops; the third was near the amino terminus of the peptide, and affected V alpha gene usage, but not the structure of CDR3 of either TCR chain. Based on these results, we propose an orientation for the TCR of this cloned line and argue for its generality.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612131     DOI: 10.1016/s1074-7613(00)80250-2

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  34 in total

Review 1.  The role of self-recognition in receptor repertoire development. Members of the Janeway Laboratory.

Authors:  C A Janeway
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. I. Recognition by two alpha beta T cell receptors.

Authors:  D Rognan; A Stryhn; L Fugger; S Lyngbaek; J Engberg; P S Andersen; S Buus
Journal:  J Comput Aided Mol Des       Date:  2000-01       Impact factor: 3.686

3.  In vitro evolution of a T cell receptor with high affinity for peptide/MHC.

Authors:  P D Holler; P O Holman; E V Shusta; S O'Herrin; K D Wittrup; D M Kranz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1.

Authors:  J Hennecke; A Carfi; D C Wiley
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

5.  Cytokine profile, HLA restriction and TCR sequence analysis of human CD4+ T clones specific for an immunodominant epitope of Mycobacterium tuberculosis 16-kDa protein.

Authors:  N Caccamo; A Barera; C Di Sano; S Meraviglia; J Ivanyi; F Hudecz; S Bosze; F Dieli; A Salerno
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

6.  A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition.

Authors:  Zarixia Zavala-Ruiz; Iwona Strug; Bruce D Walker; Philip J Norris; Lawrence J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-26       Impact factor: 11.205

7.  Structure and function of a membrane-bound murine MHC class I molecule.

Authors:  H Celia; E Wilson-Kubalek; R A Milligan; L Teyton
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

8.  Interaction of pigeon cytochrome c-(43-58) peptide analogs with either T cell antigen receptor or I-Ab molecule.

Authors:  Y Itoh; K Kajino; K Ogasawara; A Takahashi; K Namba; I Negishi; N Matsuki; K Iwabuchi; M Kakinuma; R A Good; K Onoé
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

9.  Ligand design by a combinatorial approach based on modeling and experiment: application to HLA-DR4.

Authors:  Erik Evensen; Diane Joseph-McCarthy; Gregory A Weiss; Stuart L Schreiber; Martin Karplus
Journal:  J Comput Aided Mol Des       Date:  2007-07-27       Impact factor: 3.686

10.  Conserved T-cell receptor class II major histocompatibility complex contact detected in a T-lymphocyte population.

Authors:  M Feng; D Chou; Y Liaw; M Lai
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.